Immunocore Holdings plc (IMCR) News
Filter IMCR News Items
IMCR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IMCR News Highlights
- For IMCR, its 30 day story count is now at 2.
- Over the past 5 days, the trend for IMCR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest IMCR News From Around the Web
Below are the latest news stories about IMMUNOCORE HOLDINGS PLC that investors may wish to consider to help them evaluate IMCR as an investment opportunity.
Immunocore Holdings PLC Sponsored ADR (IMCR) Upgraded to Buy: Here's What You Should KnowImmunocore Holdings PLC Sponsored ADR (IMCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
How Much Upside is Left in Immunocore Holdings PLC Sponsored ADR (IMCR)? Wall Street Analysts Think 30.32%The consensus price target hints at a 30.3% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Levicept Appoints Eliot Forster as CEOLeadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty y |
Can Immunocore Holdings PLC Sponsored ADR (IMCR) Climb 75.55% to Reach the Level Wall Street Analysts Expect?The consensus price target hints at a 75.6% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Bears are Losing Control Over Immunocore Holdings PLC Sponsored ADR (IMCR), Here's Why It's a 'Buy' NowImmunocore Holdings PLC Sponsored ADR (IMCR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
11 Best Undervalued UK Stocks To Buy NowIn this piece, we will take a look at the 11 best undervalued U.K. stocks to buy now. If you want to skip our overview of the British economy, then take a look at 5 Best Undervalued UK Stocks To Buy Now. The U.K. is one of the biggest economies in the world and a […] |
Wall Street Analysts See a 66.42% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?The mean of analysts' price targets for Immunocore Holdings PLC Sponsored ADR (IMCR) points to a 66.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business UpdateImmunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major markets with continued reimbursement expansion globally New Phase 3 clinical trial of KIMMTRAK adjuvant therapy for uveal (or ocular) melanoma (ATOM) in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) Long-term survival for KIMMTRAK in metastatic uveal melanoma demonst |
Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 01 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, will present data for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma and cutaneous melanoma at the Society for Immunotherapy |
Immunocore to present at upcoming investor conferencesImmunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 30 October 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced that management will present at the following investor conf |